肝细胞生长因子与肝纤维化

肝细胞生长因子（ＨＧＦ）是肝细胞的强有力的增殖因子，１９８９年两个研究小组几乎同时克隆出了ＨＧＦｃＤＮＡ。以后发现ＨＧＦ的作用并不限于促进肝细胞的再生，还可以抑制肝细胞的损害，改善脂肪肝，甚至还有阻止肝纤维化的作用。因此，ＨＧＦ有望作为难治性慢性肝炎和肝硬化的治疗药物。本文介绍近年来迅速开展的有关ＨＧＦ抑制肝纤维化的分子细胞学方面的研究，并以此推测ＨＧＦ的作用机制。一、ＥＣＭ与星状细胞１９６０年在研究肝纤维化的病理组织学时，发现胶原是细胞外基质（ＥＣＭ）的主要成分，主要沉积于肝细胞与肝窦的间隙即…     

八项肝纤维化血清标志物比较研究

目的比较血清血小板衍生生长因子-BB(PDGF-BB)、转化生长因子-β1(TGF-B1)、基质金属蛋白酶抑制剂-1(TIMP-1)、基质金属蛋白酶-1(MMP-1)、透明质酸(HA)、Ⅲ型前胶原(PC Ⅲ)、Ⅳ型胶原(C Ⅳ)和层黏连蛋白(LN)及外周血单个核细胞(PBMC)内TIMP-1 mRNA、MMP-1 mRNA在肝纤维化中的诊断价值。方法常规肝穿活检、组织病理学诊断；RT-PCR检测PBMCs中MMP-1 mRNA、TIMP-1 mRNA水平；酶标法检测血清PDGF-BB、TGF-β1、TIMP-1和MMP-1含量；放射免疫法检测血清HA、PC Ⅲ、C-Ⅳ和LN含量。结果经ROC曲线分析，血清PDGF-BB、TIMP-1、HA、PC Ⅲ、C-Ⅳ、LN和TIMP-1 mRNA的AUC分别为0．985、0．726、0．318、0．728、0．727、0．583、0．463、0．876；血清PDGF-BB和PBMCs中TIMP-1 mRNA的灵敏度和特异度分别为90％、95％，73．7％、100％；两者联合检测的灵敏度为97．4％，特异度为95．0％。结论八项指标中，血清PDGF-BB的诊断价值最大。在筛选肝纤维化患者时，以血清PDGF-BB、PBMC中TIMP-1 mRNA联合检测最佳。     

晚期血吸虫病肝纤维化指标与肝组织病理学的相关性研究、

目的探讨转化生长因子-β1（TGF-β1）、基质金属蛋白酶-1（MMP-1）及其组织抑制因子-1（TIMP-1）在晚期血吸虫病（晚斑）肝组织和血清中的表达及其与肝组织病理学的关系。方法采用免疫组化sP法检测45例晚血（观察组）肝组织中TGF-β1、MMP-1、TIMP-1表达;采用EIASA法检测观察组和30例健康人（对照组）血清TIMP-1、TGF-β1、MMP-1水平。结果观察组肝组织中TGF-β1、TIMP-1表达强度与肝纤维化程度、有无合并HBV感染呈正相关（P均〈0．05）;而MMP-1无相关性。与对照组比较,观察组血清TGF-β1、TIMP-1水平及TIMP-1／MMP-1值明显增高（P均〈0．01）,并与肝纤维化程度、免疫组化表达强度呈正相关（P均〈0．01）,而血清MMP-1差异无统计学意义。结论TGF-β1、MMP-1、TIMP-1与晚血肝纤维化的发生、发展密切相关,三者联合检测可作为晚血患者肝纤维化诊断和疗效评估指标。     

加强抗肝纤维化作用机制的研究

过去20年间，肝纤维化的研究取得了长足进展，表现在：（1）肝纤维化的分子病理机制逐渐了解，尤其是肝星状细胞激活的调控机制，如转化生长因子β1（TGFβ1）信号转导等的外部机制，以及维生素A信号转导等内部机制。（2）慢性肝病患者尤其是丙型肝炎患者发展为肝纤维化的自然进程、影响肝纤维化发展的遗传与环境因素、肝纤维化诊断方法等基本了解。（3）证实肝纤维化与一定程度的肝硬化都是可逆的。     

大鼠肝纤维化逆转机制研究

本实验应用腹腔注射无菌 40 %ＣＣＬ4溶液的方法[1] 造成大鼠肝纤维化自发逆转模型及不能逆转模型 ,观察平滑肌α肌动蛋白 (α ＳＭＡ)、基质金属蛋白酶及其抑制剂表达的动态变化 ,探讨了调解逆转的生物学机制。材料和方法一、材料雄性Ｗｉｓｔａｒ大鼠 64只 ,每只重 2 0 0～ 3     

姜黄素抗血吸虫病肝纤维化作用机制的研究

目的探讨姜黄素（CUR）在血吸虫病肝纤维化治疗中的作用。方法将60只小鼠随机分为6组，分别为对照组，感染组，溶剂组，CUR组（分低、中、高3个剂量）。CUR组于感染后第4周末开始通过灌胃给予CUR，感染后第10周末处死各组小鼠，剖取肝脏测定肝组织羟脯氨酸（Hyp），并检测肝脏基质金属蛋白酶-1（MMP-1）mRNA和组织金属蛋白酶抑制因子-1（TIMP-1）mRNA的表达水平。结果与感染组比较，肝组织中Hyp、胶原在CUR（低、中、高）组降低显著（tHyp=4．52、3，16、2．52，P〈0．05、P〈0，01；t胶原=33．72、23．54、18．80，P〈0．05、P〈0．01）；反转录PCR结果显示，随着CUR剂量的增加，MMP-1mRNA的表达逐渐升高。TIMP-1mRNA的表达逐渐降低，与感染组相比差异有统计学意义（tMMP-1=16．98、21．43、25．49，P〈0．05、P〈0．01；hTDMP-1=40．20、37．59、34．23．P〈0．05、P〈0．01）。结论CUR有减轻肝组织损伤程度，延缓和阻止肝纤维化发生发展的作用，此作用可能与上调MMP-1，阻止TIMP-1的产生有关。     

转化生长因子β1疫苗对肝纤维化大鼠基质金属蛋白酶-2及基质金属蛋白酶组织抑制因子-2表达的影响

转化生长因子β1（TGFβ1）是肝纤维化的启动、进展乃至肝硬化的形成中发挥核心作用的细胞因子，是激活肝星状细胞（HSC）并促进其表达细胞外基质（ECM）的关键因素。我们曾提出构建TGFβ1抗原编码序列与乙型肝炎核心抗原（HBcAg）编码序列的融合基因，将TGFβ1构建为疫苗，刺激机体产生抗体，中和自体产生的过量的TGFβ1，从而达到预防和治疗纤维化的目的。本研究旨在探讨该融合蛋白对实验性肝纤维化大鼠肝组织基质金属蛋白酶-2（MMP-2）和基质金属蛋白酶组织抑制因子-2（TIMP-2）表达的影响，以期能进一步证实TGFβ1疫苗在肝纤维化治疗中的作用，现报道如下。     

肝复健方对大鼠免疫性肝纤维化的干预作用及机制

目的观察以"浊毒"立论的肝复健方抗大鼠肝纤维化(HF)的作用及机制。方法 SD大鼠腹腔注射猪血清0.5 ml,2次/w,连续8 w制备HF模型,每天灌胃分别给予不同剂量的肝复健方和秋水仙碱治疗至12 w末。实验结束后,观察肝组织病理改变,放射免疫分析法检测血清透明质酸(HA)、层黏连蛋白(LN)、Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(CⅣ)、瘦素(Leptin)水平,RT-PCR法检测基质金属蛋白酶(MMP)-1 mRNA的表达。结果所有给药组肝脏损伤程度均较模型组减轻,肝复健方高剂量组肝脏结构改善最为明显。与模型组比较,肝复健方各给药组血清HA、LN、PCⅢ、CⅣ、Leptin水平明显降低(P0.05),与对照组比较,模型组及各药物组MMP-1表达明显减弱;经肝复健方治疗后大鼠肝脏MMP-1表达均比模型组增强。结论肝复健方能降低血清Leptin水平,增强MMP-1的表达,减轻免疫性HF大鼠的肝细胞损伤,调节细胞外基质的代谢,从而阻止或逆转HF。     

肝细胞生长因子与肝纤维化的研究进展

肝细胞生长因子是一种具有多种生物活性的细胞因子,其在促进肝细胞增殖、抑制肝星状细胞活化等方面有重要作用.肝纤维化进展过程中,各种因素引起肝细胞持续损伤,使损伤部位肝细胞再生,肝星状细胞激活,细胞外基质大量沉积,从而导致肝纤维化形成.此文就肝细胞生长因子的生物学特性及其在肝纤维化中发挥的作用作一综述.     

结缔组织生长因子与肝纤维化

结缔组织生长因子(connective tissue growth factor，CTGF)是一种新发现的细胞因子，是细胞外间质及纤维化领域新的研究热点。本重点讨论CTGF的结构、功能以及在肝纤维化形成中的作用，从而为有效防治肝纤维化提供理论依据。     

Effect of matrine on transforming growth factor β1 and hepatocyte growth factor in rat liver fibrosis model

Objective:To observe the preventive and control effect of matrine on transforming growth factor(TCF- β1) and hepatocyte.growth factor(HCF) of liver fibrosis tissue in rals.Methods:A total of48 SD rats were randomly divided into A,B,C,D groups with 12 in each,group A as the normal control group and groups B.C,D as liver fibrosis models using composite modulus method with carbon tetrachloride(CCL_4).Group B was the model group,group C adopted γ— interferon lavage therapy in the second day of modeling,and group D adopted matrine lavage treatment,at 4 and8 weeks after treatment.Six rats were executed for detection of TGF- β1 and HGF,liver tissue histology and comparison fibrosis degree changes of rat liver tissue between groups.Results:Croups B,C,D showed a more significantly increased TCF- β1 at each time point compared with group A(P0.05);Group B showed a more significantly increased TGF- β1 than groups C and D at weeks 4 and 8(P0.05);group D showed a lowest level of TGF-β1,followed by groups C and B.HGF of group B decreased more significantly than A group at weeks 4 and 8(P0.05);HGF of groups C and D was significantly elevated at 4 and 8 weeks than groups A and B(P0.05),in which the group D showed the highest level of HGF.According to tissue histologic observation,rat liver tissue structure of group A was clear and normal,tissue structure of group B was destroyed with obvious fibrous tissue hyperplasia and fatty change of hepatic cells;groups C and D showed a slighter liver tissue damage,cell necrosis and connective tissue hyperplasia in collect abbacy than group B with a trend of obvious improvement.Conclusions:Matrine can reduce TGF- β1expression and enhance the activity of HGF,so as to realize the inhibition effect on liver fibrosis in rats.     

Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats

We investigated whether anti-transforming growth factor beta (TGF-beta) molecular intervention can halt the progression of liver fibrosis in rats. To block TGF-beta action in a specific manner, we prepared an adenovirus expressing a truncated type II TGF-beta receptor (AdTbeta-TR), which specifically inhibits TGF-beta signaling as a dominant-negative receptor. We also used an adenovirus expressing bacterial beta-galactosidase (AdLacZ) as a control adenovirus. Rats were treated with dimethylnitrosamine (DMN) for 3 weeks; then, AdTbeta-TR, AdLacZ, or saline was intravenously applied once, followed by an additional 3-week DMN treatment. The ratio between the truncated receptor and the wild-type receptor at the mRNA level was 15 at 1 week and 10 at 3 weeks after gene transfer. Immunohistostaining analysis showed that the truncated receptor was expressed mainly in septal cells including hepatic stellate cells. Liver fibrosis, as assessed by histology, hydroxyproline content, and the serum level of hyaluronic acid, progressed during the additional 3-week DMN treatment. However, in rats infected with AdTbeta-TR, the fibrosis remained at the level seen in rats given DMN for only 3 weeks. All AdTbeta-TR-treated rats remained alive, whereas DMN-treated rats infused with either AdLacZ or saline died of liver dysfunction. In the livers of AdTbeta-TR-treated rats, electron microscopy showed: 1) less accumulation of extracellular matrix proteins in the Disse's spaces; 2) regenerated hepatocytes; and 3) fat droplet-rich "quiescent" hepatic stellate cells. Our results demonstrate that TGF-beta plays a critical role in the progression of liver fibrosis, and suggest that anti-TGF-beta intervention should be therapeutic in already-established fibrotic livers, not only by suppressing fibrosis, but by facilitating hepatocyte regeneration.     

缬沙坦对肺纤维化模型的干预作用及其对肝细胞生长因子表达的影响

目的研究血管紧张素Ⅱ受体拮抗剂缬沙坦对肺纤维化模型的干预作用及其可能的机制。方法60只Wistar大鼠采用随机数字表法随机分成3组,每组20只:(1)缬沙坦组,经气管插管灌注博莱霉素(BLM)诱导肺纤维化,随后每日用缬沙坦16mg/kg灌胃进行干预;(2)模型组,气管内灌注用BLM,灌胃用生理盐水;(3)对照组,气管内灌注和灌胃均用生理盐水。各组动物于气管内灌注后第7、14、28、42天分别处死5只。取肺组织经苏木精-伊红、Masson胶原染色及测定羟脯氨酸浓度来评价治疗效果。用免疫组化及原位杂交方法分别检测转化生长因子β(TGF-β)蛋白和肝细胞生长因子(HGF)mRNA在肺内的表达。用酶联免疫吸附测定(ELISA)法检测HGF蛋白在大鼠肺组织的含量。结果缬沙坦组肺泡炎程度在第14、28、42天分别为(0·88±0·12)、(0·79±0·21)、(0·75±0·17)分,低于同期模型组的(2·05±0·25)、(1·38±0·12)、(1·19±0·11)分,差异均有统计学意义(P均<0·01);缬沙坦组肺纤维化程度在第7、28、42天分别为(0·28±0·03)、(1·74±0·18)、(1·91±0·09)分,也低于同期模型组的(0·45±0·10)、(2·08±0·32)、(2·77±0·15)分,差异均有统计学意义(P均<0·05);缬沙坦组肺组织羟脯氨酸含量在第14、42天分别为(1·08±0·13)、(1·39±0·20)μg/mg·pro,低于同期模型组的(1·45±0·19)、(2·19±0·37)μg/mg·pro,差异均有统计学意义(P均<0·01);缬沙坦组肺组织中TGF-β蛋白表达在早、晚期分别为2·27±0·30、2·05±0·18,均低于同期模型组的3·99±0·43、2·71±0·46,差异均有统计学意义(P均<0·05)。缬沙坦组HGFmRNA表达在早、晚期分别为1·61±0·20、0·52±0·19,均高于同期模型组的1·98±0·23、0·28±0·14,差异均有统计学意义(P均<0·05);缬沙坦组蛋白含量在早、晚期分别为(203±18)、(129±20)pg/ml,均高于同期模型组的(260±21)、(100±20)pg/ml,差异均有统计学意义(P均<0·05)。结论缬沙坦能减轻BLM诱导的大鼠肺纤维化,有可能通过抑制TGF-β和促进HGFmRNA的表达而实现。     

鼠肝老化进程中枯否细胞对肝细胞的影响及机制

目的研究肝脏老化时枯否细胞（ＫＣ）在肝细胞（ＨＣ）功能损害中的地位和机制．方法应用ＨＣＫＣ共同培养技术研究６，１２，１８和２４月龄大鼠（每组５只）ＫＣ对ＨＣ蛋白质合成和线粒体代谢水平的影响，并探讨了这种影响与老化ＫＣ分泌功能改变的关系．结果单独培养的２４月龄组ＨＣ蛋白质合成能力和线粒体代谢水平较６月龄组明显降低；各月龄组ＨＣ与６月龄组ＫＣ共同培养时，两指标较单独培养者均有明显增加，与２４月龄组ＫＣ共同培养时则显著降低．ＬＰＳ（１０ｎｇ／Ｌ）对单独培养的ＨＣ蛋白质合成和线粒体能量代谢无明显影响，但对共同培养系统中６月龄ＫＣ的增强作用和２４月龄ＫＣ的抑制作用具有明显的放大作用．２４月龄组ＫＣＴＮＦ、ＩＬ８、ＮＯ的分泌水平较６月龄组ＫＣ明显升高，ＰＧＥ２明显降低．各组ＫＣ受ＬＰＳ刺激后ＴＮＦ和ＮＯ水平较未刺激组均有明显升高，其增值以高月龄组为显著；６和１２月龄组ＫＣ受刺激后ＩＬ８水平明显升高，１８和２４月龄组无明显变化；ＰＧＥ２的变化规律与ＩＬ８相反．结论ＫＣ在鼠肝老化时ＨＣ受损过程中起重要作用，这可能与老化ＫＣ分泌细胞因子谱有改变，导致ＨＣ分子微生态环境变化有关．     

肝细胞生长因子与自发性高血压大鼠心肌纤维化的相关研究

目的 探讨高血压进展过程中肝细胞生长因子(hepatocyte growth facor,HGF)表达与心肌纤维化的关系及血管紧张素Ⅱ受体1(ATl)拮抗剂洛沙坦的干预作用. 方法 以不同周龄自发性高血压大鼠(SHR)为心肌纤维化模型,WKY(Wistar-Kyoto)大鼠为对照组.用洛沙坦对SHR大鼠进行治疗.各周龄组WKY、SHR大鼠及干预后的SHR大鼠处死后取心脏制成石蜡切片,利用麦松三色法检测心肌胶原,免疫组织化学方法检测心肌组织HGF,Leica Qwin彩色图像分析系统分析图片. 结果 SHR大鼠心肌胶原容积(collagen volume fraction,CVF)随周龄增长而增加,8、12、16、24和32周分别为(1.8±0.1)%、(1.8±0.1)0A、(3.8±0.4)%、(7.3±0.4)%和(13.4±1.8)%,与心肌组织HGF含量呈负相关(r=-0.8820,P<0.05).洛沙坦十预可增加HGF表达,降低CVF.结论 高血压心肌纤维化可能与心肌组织HGF抗纤维化作用降低有关,AT<,1>拮抗剂治疗可以增加心肌组织HGF表达从而改善心肌纤维化.     

Adeno-associated virus vector-mediated production of hepatocyte growth factor attenuates liver fibrosis in mice

Purpose Adeno-associated virus (AAV) vectors can achieve long-term gene expression and are now feasible for use in human gene therapy. We constructed hepatocyte growth factor (HGF) expressing AAV (AAV5-HGF) and examined its effect in two mouse hepatic fibrosis models. Methods A model of hepatic fibrosis was established by carbon tetrachloride (CCl₄) administration in Balb/c mice. After the establishment of liver fibrosis, AAV5-HGF was injected once into the portal vein. Mice were killed 3, 6, 9, and 12 weeks after injection. Another model was established by bile duct ligation (BDL). Seven weeks after AAV5-HGF injection, mice underwent BDL, and were then killed 2 weeks after BDL. Results Mice that received AAV5-HGF achieved stable HGF expression both in the serum and liver for at least 12 weeks. In both models, significant improvement of the liver fibrosis was found in all mice receiving AAV5-HGF based on Azan-Mallory staining. Suppression of hepatic stellate cells (HSC) was confirmed by immunohistochemistry. Fibrogenic markers were significantly suppressed and collagenase activity increased in the livers of mice receiving AAV5-HGF. Conclusions A single injection of AAV vector containing HGF gene achieved long-term expression of HGF and resulted in resolution of mouse liver fibrosis. HGF gene therapy mediated by AAV is feasible for the treatment of liver fibrosis.     

肝细胞生长因子与肝再生增强因子重组表达质粒对大鼠肝纤维化的影响

目的 研究肝细胞生长因子(HGF)与肝再生增强因子(ALR)重组表达质粒对大鼠实验性肝纤维化的治疗作用.方法 建立二甲基亚硝胺肝纤维化模型后的90只S-D大鼠分为空白组、pcDNA3.1治疗组、pcDNA3.1-HGF治疗组、pcDNA3.1-ALR治疗组、pcDNA3.1-HGF与pcDNA3.1-ALR共治疗组、pcDNA3.1-HGF-ALR治疗组,每组15只.各治疗组大鼠每24小时经尾静脉注射1次相应质粒0.1 μmol,连续3次,空白组不接受任何治疗,另取同批次S-D大鼠10只作为对照组.治疗结束后4 d处死大鼠,留取肝组织采用HE染色观察肝脏的病理形态,采用免疫组织化学染色检测增殖细胞核抗原(PCNA)和c-jun的表达.计量资料采用单因素方差分析,两两比较采用SNK检验,计数资料采用Fisher确切概率法分析.结果 空白组和pcDNA3.1治疗组大鼠肝组织有明显的条索状纤维间隔形成,可见假小叶,两组肝纤维化程度差异无统计学意义(x2=0.317,P=1. 000);其他治疗组肝纤维化均有不同程度改善,以pcDNA3.1-HGF-ALR治疗组改善最明显.对照组肝组织PCNA和c-jun表达均较低,其吸光度值分别为8.6±1.9和3.2±1.2;空白组与pcDNA3.1治疗组肝组织PCNA和c-jun表达均增加,其吸光度值分别为24.1±3.0.24.5±4.3与23.8±3.1、24.9±4.2,与对照组比较,差异有统计学意义(均P＜0.01);其他治疗组的PCNA表达显著增加,c-jun表达显著降低,均以pcDNA3.1-HGF-ALR治疗组的变化最明显.结论 重组表达质粒pcDNA3.1-HGF-ALR能较好地改善大鼠实验性肝纤维化,并可能通过促进肝细胞增殖和抑制原癌基因c-jun的表达来发挥其抗肝纤维化作用.     

肝细胞生长因子与肝再生增强因子重组表达质粒对大鼠肝纤维化的影响

Objective To evaluate the therapeutic effects of recombinant expression plasmid containing hepatocyte growth factor (HGF) and augmenter of liver regeneration (ALR) on rats with hepatic fibrosis. Methods Ninety Sprague-Dawley rats, which had been established into hepatic fibrosis models, were equally divided into 6 groups: blank group, pcDNA3.1 therapy group,pcDNA3.1-HGF therapy group, pcDNA3. 1-ALR therapy group, pcDNA3.1-HGF and pcDNA3. 1-ALR combined therapy group, and pcDNA3. 1-HGF-ALR therapy group. Zero point one μmol of blank or plasmid was injected into model rats in each group by tail vein once a day for 3 days. Model rats in blank group didn't receive any treatment. Additional 10 rats were chosen as control group, which were not given any interference during the experiment. All rats were sacrificed 4 days after end of treatment. Liver tissues were reserved for observing pathologic changes after HE staining and detecting proliferating cell nuclear antigen (PCNA) and c-jun by immunohistochemistry. Measurement data were compared by single-factor analysis of variance. Comparison between groups was done by SNK test. Enumeration data were analyzed by Fisher's exact test. Results In blank group and pcDNA3.1 therapy group, hyperplasia of fibrous connective tissue was very obvious, false lobules were formed. There was no significant difference between these two groups (x2 =0. 317,P= 1. 000).In the 4 remaining groups, hepatic fibrosis all achieved different degree of amelioration, and the therapeutic effect of pcDNA3.1-HGF-ALR was optimal. In control group, the expressions of PCNA and c-jun in liver tissues were low, with absorbance value of 8.6±1.9 and 3.2 ± 1.2, respectively. In blank group and pcDNA3. 1 therapy group, the expressions of PCNA and c-jun were obviously increased, with absorbance value of 24. 1±3.0, 24.5±4.3 and 23.8±3.1, 24.9±4.2, respectively,which were significant different from control group (all P＜0.01). In the 4 remaining groups, the expressions of PCNA were all obviously increased, and expressions of c-jun were all obviously decreased. The maximum change scope was observed in pcDNA3. 1-HGF-ALR therapy group.Conclusions The recombinant expression plasmid pcDNA3. 1-HGF-ALR can effectively ameliorate experimental hepatic fibrosis of rats. The anti-fibrosis effects are achieved probably by up-regulating PCNA expression and down-regulating c-jun expression.     

肝细胞生长因子与肝再生增强因子重组表达质粒对大鼠肝纤维化的影响

Objective To evaluate the therapeutic effects of recombinant expression plasmid containing hepatocyte growth factor (HGF) and augmenter of liver regeneration (ALR) on rats with hepatic fibrosis. Methods Ninety Sprague-Dawley rats, which had been established into hepatic fibrosis models, were equally divided into 6 groups: blank group, pcDNA3.1 therapy group,pcDNA3.1-HGF therapy group, pcDNA3. 1-ALR therapy group, pcDNA3.1-HGF and pcDNA3. 1-ALR combined therapy group, and pcDNA3. 1-HGF-ALR therapy group. Zero point one μmol of blank or plasmid was injected into model rats in each group by tail vein once a day for 3 days. Model rats in blank group didn't receive any treatment. Additional 10 rats were chosen as control group, which were not given any interference during the experiment. All rats were sacrificed 4 days after end of treatment. Liver tissues were reserved for observing pathologic changes after HE staining and detecting proliferating cell nuclear antigen (PCNA) and c-jun by immunohistochemistry. Measurement data were compared by single-factor analysis of variance. Comparison between groups was done by SNK test. Enumeration data were analyzed by Fisher's exact test. Results In blank group and pcDNA3.1 therapy group, hyperplasia of fibrous connective tissue was very obvious, false lobules were formed. There was no significant difference between these two groups (x2 =0. 317,P= 1. 000).In the 4 remaining groups, hepatic fibrosis all achieved different degree of amelioration, and the therapeutic effect of pcDNA3.1-HGF-ALR was optimal. In control group, the expressions of PCNA and c-jun in liver tissues were low, with absorbance value of 8.6±1.9 and 3.2 ± 1.2, respectively. In blank group and pcDNA3. 1 therapy group, the expressions of PCNA and c-jun were obviously increased, with absorbance value of 24. 1±3.0, 24.5±4.3 and 23.8±3.1, 24.9±4.2, respectively,which were significant different from control group (all P＜0.01). In the 4 remaining groups, the expressions of PCNA were all obviously increased, and expressions of c-jun were all obviously decreased. The maximum change scope was observed in pcDNA3. 1-HGF-ALR therapy group.Conclusions The recombinant expression plasmid pcDNA3. 1-HGF-ALR can effectively ameliorate experimental hepatic fibrosis of rats. The anti-fibrosis effects are achieved probably by up-regulating PCNA expression and down-regulating c-jun expression.